Related Experiment Video

Updated: Oct 9, 2025

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

18.9K

Transcriptional cyclin-dependent kinases: Potential drug targets in cancer therapy

Yi Liu1, Leilei Fu1, Junhao Wu2

  • 1Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University, 610031, Chengdu, China.

European Journal of Medicinal Chemistry
|December 23, 2021
PubMed

Insights

Cyclin-dependent kinases (CDKs) regulate cell cycles and transcription. Inhibiting CDKs offers potential cancer treatments, with combined strategies showing promise for future remedies.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Biochemistry

Background:

  • Cyclin-dependent kinases (CDKs) are crucial regulators of cell cycle progression.
  • Emerging evidence highlights CDKs' roles in transcriptional regulation in response to cellular signals.
  • Targeting CDK functions is a significant area of research for therapeutic interventions.

Purpose of the Study:

  • To review the biological functions of transcription-related CDKs and their complexes.
  • To discuss key upstream and downstream signaling pathways involving these CDKs.
  • To explore recent advancements in CDK inhibitors and combination therapies for cancer treatment.

Main Methods:

  • Literature review of recent studies on CDKs, transcription, and cancer therapy.
  • Analysis of signaling pathways and molecular mechanisms.
  • Evaluation of current and emerging CDK inhibitors and treatment strategies.

Main Results:

  • CDKs play a multifaceted role in regulating both cell cycle and transcription.
  • Pharmacological targets for transcription-related CDKs are still underdeveloped, with limited clinical-stage inhibitors.
  • Combination therapies involving CDK inhibitors present a promising avenue for novel cancer treatments.

Conclusions:

  • Transcription-regulating CDKs are critical targets for cancer therapy.
  • Further development of CDK inhibitors and strategic combination treatments is essential for advancing cancer remedies.
  • This perspective offers insights into future directions for cancer treatment utilizing CDK modulation.
Keywords:
Biological functionCancer therapySelective transcriptional CDKs inhibitorsTranscriptional CDKs

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.5K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.4K

Related Concept Videos

M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K